Anzeige
Mehr »
Sonntag, 06.07.2025 - Börsentäglich über 12.000 News
Surfen Sie die heißeste Edelmetall-Welle des Jahrzehnts! Dieses TOP-Unternehmen zündet nächste Wachstumsstufe!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EEZB | ISIN: US72941H5090 | Ticker-Symbol: XMP0
NASDAQ
03.07.25 | 18:28
0,301 US-Dollar
+1,38 % +0,004
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PLUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PLUS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur PLUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
PLUS THERAPEUTICS Aktie jetzt für 0€ handeln
MoPlus Therapeutics Inc.: Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ in Leptomeningeal Metastases209Primary objective to determine optimal dosing schedule for a registrational trial Trial builds on recommended Phase 2 dose determined in completed Phase 1 trial Trial benefits from $17.6M award...
► Artikel lesen
27.06.Plus Therapeutics stock price target lowered to $3 at H.C. Wainwright16
26.06.Plus Therapeutics Expects Meaningful Revenue Contributions From CNSide Diagnostics In 2026309WASHINGTON (dpa-AFX) - Plus Therapeutics, Inc. (PSTV), a clinical-stage pharmaceutical company, expects the revenue contributions of CNSide Diagnostics, LLC to 'become meaningful' in fiscal...
► Artikel lesen
26.06.FDA approves Plus Therapeutics' Reyobiq for paediatric brain cancer6
26.06.Plus Therapeutics Inc.: Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary179U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion Management to host...
► Artikel lesen
25.06.Plus Therapeutics rises after FDA clearance to begin Reyobiqtm trial4
25.06.Plus Therapeutics Stock Gains As FDA Clears REYOBIQ IND Application To Treat Pediatric Brain Cancers2
25.06.FDA genehmigt Studie für Krebsbehandlung bei Kindern von Plus Therapeutics7
25.06.Plus Therapeutics Inc.: Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer89Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll children with high grade glioma and ependymoma HOUSTON, June 25, 2025...
► Artikel lesen
24.06.Plus Therapeutics Announces Restructuring Of Its Equity Financing318WASHINGTON (dpa-AFX) - Plus Therapeutics (PSTV) announced a comprehensive restructuring of its previous $15 million equity financing announced on March 4, 2025. This strategic restructuring...
► Artikel lesen
24.06.Plus Therapeutics strukturiert Finanzierung von 15 Millionen US-Dollar um, um Verwässerung zu reduzieren12
24.06.Plus Therapeutics restructures $15 million financing to reduce dilution4
24.06.Plus Therapeutics Inc.: Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing284Comprehensive restructuring eliminates the potential issuance of up to 1.5 billion shares of common stock Plus Therapeutics files a request to withdraw the related resale registration statement with...
► Artikel lesen
19.06.PLUS THERAPEUTICS, INC. - S-1/A, General form for registration of securities12
18.06.Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering32
18.06.PLUS THERAPEUTICS, INC. - S-1, General form for registration of securities12
17.06.PLUS THERAPEUTICS, INC. - 8-K, Current Report4
06.06.PLUS THERAPEUTICS, INC. - 8-K, Current Report9
05.06.Ascendiant Capital raises Plus Therapeutics stock price target21
02.06.Plus Therapeutics GAAP EPS of -$1.19 misses by $0.97, revenue of $1.06M misses by $0.08M13
Weiter >>
81 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1